Five Under 5: Top Oncology Videos for the Week of 6/1

Welcome to The Five Under 5, your go-to roundup of the top 5 videos of the week.

These short videos are designed for busy oncologists to view on the go, and feature expert insights on breaking news, regulatory updates, practice-changing data shared at medical meetings, and other key topics in the realm of oncology.

This week, it’s an ASCO-exclusive Five Under 5, as we highlight some of the top interviews conducted by OncLive around the 2025 ASCO Annual Meeting.

Here’s what you may have missed:

Sara M. Tolaney, MD, MPH, of Dana-Farber Cancer Institute and Harvard Medical School, broke down the key progression-free survival benefit (PFS) data generated by fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in combination with in the phase pertuzumab (Perjeta) compared with standard-of-care trastuzumab (Herceptin) plus pertuzumab and a taxane (THP) for the first-line treatment of patients with HER2-positive advanced/metastatic breast cancer in the phase 3 DESTINY-Breast09 trial (NCT04784715).

Thomas Powles, MD, MBBS, MRCP, of Barts Cancer Centre at St. Bartholomew's Hospital, Queen Mary University of London, detailed findings from the phase 3 CREST study (NCT04165317) regarding event-free survival outcomes for sasanlimab in combination with BCG in patients with BCG-naive, high-risk non–muscle-invasive bladder cancer.

Erika Hamilton, MD, of Sarah Cannon Research Institute, discussed efficacy data for vepdegestrant (ARV-471) vs fulvestrant (Faslodex) in patients with ER-positive/HER2-negative advanced breast cancer, based on data from the phase 3 VERITAC-2 study (NCT05654623). The study met its primary end point, with vepdegestrant yielding a statistically significant improvement in progression-free survival (PFS) in patients harboring ESR1 mutations; however, this benefit was not statistically significant in the overall trial population, which included patients with and without ESR1 mutations.

Sara Char, MD, of Dana-Farber Cancer Institute, discussed findings from an exploratory analysis of phase 3 CALGB/SWOG 80702 (NCT01150045), which evaluated the association between the empirical dietary inflammatory pattern (EDIP) and survival outcomes in patients with stage III colon cancer. The study initially evaluated the addition of celecoxib vs placebo to standard adjuvant therapy in this patient population. Findings from the analysis showed that EDIP scores were not significantly associated with DFS outcomes; however, OS differences were statistically significant, with higher EDIP scores being associated with worse survival.

Jonathan W. Goldman, MD, of UCLA Health, discussed the efficacy of telisotuzumab vedotin-tllv (Emrelis) in the treatment of patients with nonsquamous, EGFR wild-type, advanced non–small cell lung cancer (NSCLC) with c-MET overexpression in the phase 2 LUMINOSITY trial (NCT03539536). In this analysis, Goldman and colleagues took a deeper look at outcomes for patients based on prior therapy.